{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tesamorelin","title":"tesamorelin","body":"## Overview\nEvidence is being populated by Grok web search.","hero":null,"images":[],"style":{},"tags":[],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T17:02:50.677Z","model":"grok/grok-4.3","rationale":""}},{"id":"c2","text":"2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T17:02:50.677Z","model":"grok/grok-4.3","rationale":""}},{"id":"c3","text":"Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s3"],"source_status":"sourced","why_material":"Materialized from orphan source s3 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T17:02:50.677Z","model":"grok/grok-4.3","rationale":""}},{"id":"c4","text":"2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s4"],"source_status":"sourced","why_material":"Materialized from orphan source s4 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T17:02:50.677Z","model":"grok/grok-4.3","rationale":""}},{"id":"c5","text":"New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s5"],"source_status":"sourced","why_material":"Materialized from orphan source s5 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T17:02:50.677Z","model":"grok/grok-4.3","rationale":""}}],"sources":[{"id":"s1","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials","quote":"Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects","summary":"2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety.","author":"","publisher":"","date":"","claim_ids":["c1"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:02:16.304Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"deafc06c6a5f7dd98046e0b6a03e987a26199afe00bced2939cfbffb562e4a2a"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39813152/","title":"Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity","quote":"Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression.","summary":"2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.","author":"","publisher":"","date":"","claim_ids":["c2"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:02:16.304Z","link_status":"ok","quote_status":"verified","prev":"deafc06c6a5f7dd98046e0b6a03e987a26199afe00bced2939cfbffb562e4a2a","hash":"55299462964e592ea141f1e0dc057b544541bcbbfc813ba0e518e9a99671f493"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV (TRIUMPH Trial)","quote":"The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise.","summary":"Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health.","author":"","publisher":"","date":"","claim_ids":["c3"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:02:16.304Z","link_status":"ok","quote_status":"unverified","prev":"55299462964e592ea141f1e0dc057b544541bcbbfc813ba0e518e9a99671f493","hash":"6de042dc8ae1370de1f77c3484269d514dbb51fb7a337c1117e3fb8e6a339c99"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors","quote":"The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.","summary":"2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated.","author":"","publisher":"","date":"","claim_ids":["c4"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:02:38.241Z","link_status":"ok","quote_status":"verified","prev":"6de042dc8ae1370de1f77c3484269d514dbb51fb7a337c1117e3fb8e6a339c99","hash":"66cdb2a41d7ebb7b1d409e1b48f6d5cd17e0858f7c8c16ba81fd9f424b989abb"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07481734","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","quote":"This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.","summary":"New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD.","author":"","publisher":"","date":"","claim_ids":["c5"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:02:38.241Z","link_status":"ok","quote_status":"unverified","prev":"66cdb2a41d7ebb7b1d409e1b48f6d5cd17e0858f7c8c16ba81fd9f424b989abb","hash":"853bbca219795e5e5a1825104340e3c7020244c0910c40ee6861ceb960cf1b90"}],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":2,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:02:00.279Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"tesamorelin","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"24b3f450bec2390a00bad077c0d43c08fe7d2b012d89788c539a79400f565a09"},{"seq":1,"id":"k2","ts":"2026-06-29T17:02:16.853Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials","quote":"Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39813152/","title":"Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity","quote":"Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV (TRIUMPH Trial)","quote":"The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"24b3f450bec2390a00bad077c0d43c08fe7d2b012d89788c539a79400f565a09","hash":"2f7e2e52bf644143d11909969ffdf4d9b5e2588f675c9e1d87f10b407ea2540a"},{"seq":2,"id":"k3","ts":"2026-06-29T17:02:38.960Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors","quote":"The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07481734","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","quote":"This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"2f7e2e52bf644143d11909969ffdf4d9b5e2588f675c9e1d87f10b407ea2540a","hash":"44e64c3ee65f1c89bf293517c0592345f045c306b572ff4f19860e1bcd569fff"}],"provenance":[{"ts":"2026-06-29T17:02:00.279Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"0babaa2e262fdd704b1522e19c677929302af5be5e35626291835a085039f5a4"},{"ts":"2026-06-29T17:02:16.853Z","model":"grok-4.3","action":"sources","prompt":"","input":"tesamorelin","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0babaa2e262fdd704b1522e19c677929302af5be5e35626291835a085039f5a4","hash":"fa52669b26693625877777ff7976d3018a6d475ea99a80c480be6d3ce7baec19"},{"ts":"2026-06-29T17:02:38.960Z","model":"grok-4.3","action":"sources","prompt":"","input":"tesamorelin","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fa52669b26693625877777ff7976d3018a6d475ea99a80c480be6d3ce7baec19","hash":"52516271d6b330a3b387b8fc5be9257958b34e40ff0f350b7fbbdbbfe8fd2e7d"},{"ts":"2026-07-17T02:42:19.974Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin","response":"2 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"52516271d6b330a3b387b8fc5be9257958b34e40ff0f350b7fbbdbbfe8fd2e7d","hash":"23ab06468a63ec8f887821671a5209e4abebf3ed884d87212fdebd7e944fe26e"}],"energy":{"passes":4,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":3,"owner":1},"head":"23ab06468a63ec8f887821671a5209e4abebf3ed884d87212fdebd7e944fe26e"},"posted_at":"2026-06-29T17:02:00.279Z","created_at":"2026-06-29T17:02:00.279Z","updated_at":"2026-07-17T02:42:19.974Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin","json":"https://miscsubjects.com/api/articles/tesamorelin","bundle":"https://miscsubjects.com/api/articles/tesamorelin/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":3,"revisions":2,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin","json":"/api/articles/tesamorelin","markdown":"/api/articles/tesamorelin/bundle?format=markdown","skill":"/api/articles/tesamorelin/skill","topology":"/api/articles/tesamorelin/topology","versions":"/api/articles/tesamorelin/revisions","invocations":"/api/articles/tesamorelin/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin","ok":false,"issues":[{"code":"headline_quality","message":"headline is too short to orient a cold reader; name the subject and event: \"tesamorelin\"","replacement":"Write a shorter literal headline naming the article subject and its central event or claim."},{"code":"heading_filing_label","message":"section heading “Overview” is a filing label that gives a cold reader no claim","replacement":"Replace “Overview” with the concrete claim, event, or object introduced in that section."},{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"dcd6b7bdb3704e6e308dd7c9e774bd45269f7b4d7d44b04b150e3024d021c061","object":{"object_type":"article-object","identity":{"id":"article:tesamorelin","slug":"tesamorelin","title":"tesamorelin"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tesamorelin","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tesamorelin/skill","role":"direct behavior","audience":"model","content":"---\nname: tesamorelin\ndescription: Apply the tesamorelin article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# tesamorelin\n\nThis Skill is the behavioral expression of [the canonical article](/a/tesamorelin). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tesamorelin.\n- Read claims and relationships at /api/articles/tesamorelin/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nOverview Evidence is being populated by Grok web search.\n\n## Representations\n\n- Human: /a/tesamorelin\n- JSON: /api/articles/tesamorelin\n- Relationships: /api/articles/tesamorelin/topology\n- History: /api/articles/tesamorelin/revisions\n"},"json":{"route":"/api/articles/tesamorelin","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tesamorelin/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["tesamorelin"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tesamorelin/invocations?status=success","failure_events":"/api/articles/tesamorelin/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tesamorelin","title":"tesamorelin","body":"## Overview\nEvidence is being populated by Grok web search.","hero":null,"images":[],"style":{},"tags":[],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T17:02:50.677Z","model":"grok/grok-4.3","rationale":""}},{"id":"c2","text":"2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T17:02:50.677Z","model":"grok/grok-4.3","rationale":""}},{"id":"c3","text":"Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s3"],"source_status":"sourced","why_material":"Materialized from orphan source s3 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T17:02:50.677Z","model":"grok/grok-4.3","rationale":""}},{"id":"c4","text":"2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s4"],"source_status":"sourced","why_material":"Materialized from orphan source s4 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T17:02:50.677Z","model":"grok/grok-4.3","rationale":""}},{"id":"c5","text":"New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s5"],"source_status":"sourced","why_material":"Materialized from orphan source s5 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T17:02:50.677Z","model":"grok/grok-4.3","rationale":""}}],"sources":[{"id":"s1","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials","quote":"Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects","summary":"2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety.","author":"","publisher":"","date":"","claim_ids":["c1"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:02:16.304Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"deafc06c6a5f7dd98046e0b6a03e987a26199afe00bced2939cfbffb562e4a2a"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39813152/","title":"Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity","quote":"Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression.","summary":"2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.","author":"","publisher":"","date":"","claim_ids":["c2"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:02:16.304Z","link_status":"ok","quote_status":"verified","prev":"deafc06c6a5f7dd98046e0b6a03e987a26199afe00bced2939cfbffb562e4a2a","hash":"55299462964e592ea141f1e0dc057b544541bcbbfc813ba0e518e9a99671f493"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV (TRIUMPH Trial)","quote":"The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise.","summary":"Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health.","author":"","publisher":"","date":"","claim_ids":["c3"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:02:16.304Z","link_status":"ok","quote_status":"unverified","prev":"55299462964e592ea141f1e0dc057b544541bcbbfc813ba0e518e9a99671f493","hash":"6de042dc8ae1370de1f77c3484269d514dbb51fb7a337c1117e3fb8e6a339c99"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors","quote":"The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.","summary":"2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated.","author":"","publisher":"","date":"","claim_ids":["c4"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:02:38.241Z","link_status":"ok","quote_status":"verified","prev":"6de042dc8ae1370de1f77c3484269d514dbb51fb7a337c1117e3fb8e6a339c99","hash":"66cdb2a41d7ebb7b1d409e1b48f6d5cd17e0858f7c8c16ba81fd9f424b989abb"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07481734","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","quote":"This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.","summary":"New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD.","author":"","publisher":"","date":"","claim_ids":["c5"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:02:38.241Z","link_status":"ok","quote_status":"unverified","prev":"66cdb2a41d7ebb7b1d409e1b48f6d5cd17e0858f7c8c16ba81fd9f424b989abb","hash":"853bbca219795e5e5a1825104340e3c7020244c0910c40ee6861ceb960cf1b90"}],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":2,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:02:00.279Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"tesamorelin","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"24b3f450bec2390a00bad077c0d43c08fe7d2b012d89788c539a79400f565a09"},{"seq":1,"id":"k2","ts":"2026-06-29T17:02:16.853Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials","quote":"Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39813152/","title":"Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity","quote":"Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV (TRIUMPH Trial)","quote":"The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"24b3f450bec2390a00bad077c0d43c08fe7d2b012d89788c539a79400f565a09","hash":"2f7e2e52bf644143d11909969ffdf4d9b5e2588f675c9e1d87f10b407ea2540a"},{"seq":2,"id":"k3","ts":"2026-06-29T17:02:38.960Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors","quote":"The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07481734","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","quote":"This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"2f7e2e52bf644143d11909969ffdf4d9b5e2588f675c9e1d87f10b407ea2540a","hash":"44e64c3ee65f1c89bf293517c0592345f045c306b572ff4f19860e1bcd569fff"}],"provenance":[{"ts":"2026-06-29T17:02:00.279Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"0babaa2e262fdd704b1522e19c677929302af5be5e35626291835a085039f5a4"},{"ts":"2026-06-29T17:02:16.853Z","model":"grok-4.3","action":"sources","prompt":"","input":"tesamorelin","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0babaa2e262fdd704b1522e19c677929302af5be5e35626291835a085039f5a4","hash":"fa52669b26693625877777ff7976d3018a6d475ea99a80c480be6d3ce7baec19"},{"ts":"2026-06-29T17:02:38.960Z","model":"grok-4.3","action":"sources","prompt":"","input":"tesamorelin","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fa52669b26693625877777ff7976d3018a6d475ea99a80c480be6d3ce7baec19","hash":"52516271d6b330a3b387b8fc5be9257958b34e40ff0f350b7fbbdbbfe8fd2e7d"},{"ts":"2026-07-17T02:42:19.974Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin","response":"2 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"52516271d6b330a3b387b8fc5be9257958b34e40ff0f350b7fbbdbbfe8fd2e7d","hash":"23ab06468a63ec8f887821671a5209e4abebf3ed884d87212fdebd7e944fe26e"}],"energy":{"passes":4,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":3,"owner":1},"head":"23ab06468a63ec8f887821671a5209e4abebf3ed884d87212fdebd7e944fe26e"},"posted_at":"2026-06-29T17:02:00.279Z","created_at":"2026-06-29T17:02:00.279Z","updated_at":"2026-07-17T02:42:19.974Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin","json":"https://miscsubjects.com/api/articles/tesamorelin","bundle":"https://miscsubjects.com/api/articles/tesamorelin/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":3,"revisions":2,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin","json":"/api/articles/tesamorelin","markdown":"/api/articles/tesamorelin/bundle?format=markdown","skill":"/api/articles/tesamorelin/skill","topology":"/api/articles/tesamorelin/topology","versions":"/api/articles/tesamorelin/revisions","invocations":"/api/articles/tesamorelin/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin","ok":false,"issues":[{"code":"headline_quality","message":"headline is too short to orient a cold reader; name the subject and event: \"tesamorelin\"","replacement":"Write a shorter literal headline naming the article subject and its central event or claim."},{"code":"heading_filing_label","message":"section heading “Overview” is a filing label that gives a cold reader no claim","replacement":"Replace “Overview” with the concrete claim, event, or object introduced in that section."},{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"dcd6b7bdb3704e6e308dd7c9e774bd45269f7b4d7d44b04b150e3024d021c061"}}}